FAKTOR-OPTIONSSCHEIN - BIOGEN IDEC | Delayed Deutsche Boerse AG 09:11:10 13/05/2024 pm IST | ||
| 4.2 EUR | +1.94% |
|
| Current month | +14.13% | ||
| 1 month | +40.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 4.2 | +1.94% | 0 |
| 10/24/10 | 4.12 | +0.98% | 0 |
| 09/24/09 | 4.08 | +1.49% | 0 |
| 08/24/08 | 4.02 | +4.42% | 0 |
| 07/24/07 | 3.85 | -4.23% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 09:11 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SN3KAX |
| ISIN | DE000SN3KAX7 |
| Date issued | 17/06/2022 |
| Strike | 196.9 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 35.77 € |
|---|---|
| Lowest since issue | 2.24 € |
| Spread | 0.02 € |
| Spread % | 0.47% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
221.5
USD
Average target price
285.9
USD
Spread / Average Target
+29.08%
- Stock Market
- Certificates
- Certificat